RayKnowChina Research Map
Shortlist

RecruitingLymphomaEarly phase 1

Registered title, quoted from ClinicalTrials.gov

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)First Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06716164, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 19 years to 70 years; sex: all

    Registered eligibility fields

  2. At least one measurable lesion at baseline, according to the Preliminary Assessment, staging and Response Assessment recommendations for Hodgkin's and non-Hodgkin's lymphoma (2014 edition);

    Inclusion criterion 10

  3. After treatment with these regimens, patients maintain SD (SD duration ≤ 12 months) or still progress;

    Inclusion criterion 5

    If the subject has progressed or relapsed after prior CD19 CAR-T cell therapy, the planned apheresis phase should be at least 1 month after that, or the subject has been treated with other biologics, but is in the washout period;

    Inclusion criterion 9

    Complete blood count (CBC) test [the following criteria should be met within 24 hours prior to apheresis, and supportive treatment such as transfusion, platelet transfusion, cell growth factor (except recombinant erythropoietin) should be avoided within 7 days prior to detection]

    Inclusion criterion 14

    Patients who had received chemotherapy other than preconditioning chemotherapy within 2 weeks prior to Meta10-19 infusion;

    Exclusion criterion 2

  4. Platelet count ≥ 25×109/L;

    Inclusion criterion 16

    Hemoglobin ≥ 70.0 g/L

    Inclusion criterion 17

    Serum creatinine (Scr) ≤ 1.5 x ULN, or

    Inclusion criterion 19

    endogenous creatinine clearance ≥ 40 mL/min (using Cockcroft-Gault formula);

    Inclusion criterion 20

    alanine aminotransferase (ALT) ≤ 2.5 x ULN;

    Inclusion criterion 21

    aspartate aminotransferase (AST) ≤ 2.5 ×ULN;

    Inclusion criterion 22

    Total bilirubin (TBIL) ≤ 2 ×ULN; Subjects with total bilirubin < 3 × ULN and direct bilirubin < 1.5× ULN with Gilbert-.Meulengracht syndrome could be included;

    Inclusion criterion 23

    Serum lipase and amylase ≤ 1.5×ULN;

    Inclusion criterion 24

    Alkaline phosphatase (ALP) ≤ 2.5 ×ULN;

    Inclusion criterion 25

    In case of bone or liver metastasis, AST, ALT and ALP ≤ 5 ×ULN;

    Inclusion criterion 26

    Prothrombin time (PT) extended ≤ 4 s, fibrinogen ≥ 1 g/L, activated partial thromboplastin time (APTT) ≤ 1.5 ×ULN;

    Inclusion criterion 27

  5. Patients with active hepatitis B (defined as hepatitis B surface antigen positive or hepatitis B core antibody positive, concomitant hepatitis B virus DNA level > 1000 copies/ml) or hepatitis C (HCV RNA positive);

    Exclusion criterion 4

    Patients with HIV antibody positive or treponema pallidum antibody positive;

    Exclusion criterion 5

    Carcinoma in situ (DCIS) of cervical or breast cancer, which has been treated therapeutically, has shown no signs of recurrence for at least 3 years prior to the signing of the informed consent;

    Exclusion criterion 10

    The primary malignancy has been completely resected and in complete remission for ≥5 years;

    Exclusion criterion 11

  6. Women of childbearing age and all male patients must consent to use a effective contraception for at least 12 months after Meta10-19 infusion and until two consecutive PCR tests show no more CAR T cells in vivo.

    Inclusion criterion 36

    Women who are pregnant or breastfeeding (pregnancy tests for women of childbearing age are positive);

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06716164, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • All subjects or guardians must sign an informed consent form approved by the Ethics Committee in person before commencing any screening process;
  • Age > 18 years old, ≤ 70 years old, male or female;
  • Diagnosis of relapsed/refractory (R/R) indolent B-cell lymphoma, and/or R/R diffuse large B-cell lymphoma (DLBCL). Refractory diseases are defined as one of the following:
  • Patients with relapsed or refractory B-cell lymphoma treated with one standard treatment regimen and one salvage regimen treated with rituximab or another CD20 antibody drug and at least two treatment regiments appropriate for their disease, one of which should include anthracyclines;
  • After treatment with these regimens, patients maintain SD (SD duration ≤ 12 months) or still progress;
  • Recurrence after autologous hematopoietic stem cell transplantation, or recurrence of allogeneic HSCT, or inability to accept HSCT for various reasons;
  • Patients with double-strike or triple-strike B-cell lymphoma who did not respond to second-line therapy;
  • CD19 expression was positive by immunohistochemistry or flow cytometry (accept the results of this peripheral blood mononuclear cells or previous report from a Class A tertiary hospital before peripheral blood collection);
  • If the subject has progressed or relapsed after prior CD19 CAR-T cell therapy, the planned apheresis phase should be at least 1 month after that, or the subject has been treated with other biologics, but is in the washout period;
  • At least one measurable lesion at baseline, according to the Preliminary Assessment, staging and Response Assessment recommendations for Hodgkin's and non-Hodgkin's lymphoma (2014 edition);
  • Expected survival time greater than 12 weeks;
  • ECOG score 0-1 (subjects with central nervous system diseases caused by leukemia or lymphoma need to be determined by the investigator);
  • Organ function:
  • Complete blood count (CBC) test [the following criteria should be met within 24 hours prior to apheresis, and supportive treatment such as transfusion, platelet transfusion, cell growth factor (except recombinant erythropoietin) should be avoided within 7 days prior to detection]
  • Lymphocyte count ≥ 0.5×109/L (except for those receiving bridging chemotherapy);
  • Platelet count ≥ 25×109/L;
  • Hemoglobin ≥ 70.0 g/L
  • Blood Biochemistry:
  • Serum creatinine (Scr) ≤ 1.5 x ULN, or
  • endogenous creatinine clearance ≥ 40 mL/min (using Cockcroft-Gault formula);
  • alanine aminotransferase (ALT) ≤ 2.5 x ULN;
  • aspartate aminotransferase (AST) ≤ 2.5 ×ULN;
  • Total bilirubin (TBIL) ≤ 2 ×ULN; Subjects with total bilirubin < 3 × ULN and direct bilirubin < 1.5× ULN with Gilbert-.Meulengracht syndrome could be included;
  • Serum lipase and amylase ≤ 1.5×ULN;
  • Alkaline phosphatase (ALP) ≤ 2.5 ×ULN;
  • In case of bone or liver metastasis, AST, ALT and ALP ≤ 5 ×ULN;
  • Prothrombin time (PT) extended ≤ 4 s, fibrinogen ≥ 1 g/L, activated partial thromboplastin time (APTT) ≤ 1.5 ×ULN;
  • Pulmonary function: ≤CTCAE grade 1 dyspnea and oxygen saturation of blood (SaO2) > 91% in indoor air environment..
  • Hemodynamic stability was determined by echocardiography or multichannel radionuclide angiography (MUGA) and LVEF ≥45%;
  • Patients using the following drugs must meet the following conditions:
  • Steroid: Therapeutic doses of steroids must be discontinued 2 weeks prior to Meta10-19 infusion. However, physiological replacement doses of steroids are permitted, hydrocortisone or its equivalent < 6-12mg/mm2/ day;
  • Immunosuppressive agent: Any immunosuppressive drug must be stopped ≥4 weeks before the informed consent is signed;
  • Stop all anti-proliferation therapies other than preconditioning chemotherapy in the 2 weeks before Meta10-19 infusion;
  • Treatment for CNS disease must be stopped 1 week before Meta10-19 infusion (e.g., intrathecal methotrexate)
  • The patient has recovered from the toxicity of the previous treatment, that is, the CTCAE toxicity grade is less than 1 (The exception is specific toxicity of grade 2 or less, such as hair loss, which the researchers have determined is not recoverable in a short period of time) is suitable for pretreatment chemotherapy and CAR-T cell therapy;
  • Women of childbearing age and all male patients must consent to use a effective contraception for at least 12 months after Meta10-19 infusion and until two consecutive PCR tests show no more CAR T cells in vivo.

Exclusion Criteria:

  • Patients with present or history of central nervous system diseases not associated with leukemia or lymphoma, such as seizures disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement;
  • Patients who had received chemotherapy other than preconditioning chemotherapy within 2 weeks prior to Meta10-19 infusion;
  • Patients who participated in other clinical trials within 30 days prior to enrollment;
  • Patients with active hepatitis B (defined as hepatitis B surface antigen positive or hepatitis B core antibody positive, concomitant hepatitis B virus DNA level > 1000 copies/ml) or hepatitis C (HCV RNA positive);
  • Patients with HIV antibody positive or treponema pallidum antibody positive;
  • Patients with uncontrolled acute life-threatening bacterial, viral or fungal infections (e.g. positive blood cultures ≤72 hours before Meta10-19 infusion);
  • History of unstable angina and/or myocardial infarction within 6 months prior to signing the informed consent; History of uncontrolled thrombotic events, major bleeding, or deep venous thrombosis (DVT) within 12 months prior to signing the informed consent;
  • Patients with history of other malignancies, but the following conditions can be enrollment:
  • Adequately treated basal or squamous cell carcinoma (requiring adequate wound healing before signing informed consent);
  • Carcinoma in situ (DCIS) of cervical or breast cancer, which has been treated therapeutically, has shown no signs of recurrence for at least 3 years prior to the signing of the informed consent;
  • The primary malignancy has been completely resected and in complete remission for ≥5 years;
  • Women who are pregnant or breastfeeding (pregnancy tests for women of childbearing age are positive);
  • History of QT interval prolongation or severe cardiac disease;
  • Before signing the informed consent form, the ADA (FMC63) test was significantly positive (the test result was weakly positive, and it was necessary to discuss with the investigator whether to rule it out);
  • Other conditions that the investigator considered should not be enrolled in this clinical study.

Quoted from ClinicalTrials.gov, NCT06716164, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06716164, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06716164